To perform an economic evaluation (EE) comparing eletriptan 40 mg with available standard doses of existing triptans in Spain using different outcome measurements of anti-migraine effectiveness. METHODS: A cost-effectiveness analysis was performed comparing eletriptan (E) versus existing triptans available in Spain in year 2002; sumatriptan (S), almotriptan (A), naratriptan (N), rizatriptan (R) y zolmitriptan (Z). Effectiveness was obtained from a meta-analysis of efficacy with published randomized clinical trials (RCT). Effectiveness measurements were analgesic response within 2 hours (pain reduction and pain free), usage of rescue medication, and 24 hours response (sustained pain free and recurrence rate). Number needed to treat (NNT), with its 95% confidence interval was calculated. EE was performed from the National Health System perspective and drugs cost are computed only using public selling prices. RESULTS: A total of 33 RCTs were used to ascertain triptans effectiveness (9.473 patients treated with triptans and 3.432 with placebo). The proportion of patients with headache response within 2 hours was higher with eletriptan than with the rest of triptans; 38% versus, respectively, 28%, 25%, 23%, 37%, & 25% for S, Z, N, R, and A. E showed a lower NTT per successfully treated attacks than comparators; 2,6 vs, respectively, 3.6, 4.0, 4.3, 2.7, 4.0, and 2.6. The cost per successfully treated patient was lower for E; €26.54 versus €30.61, €45.95, €29.69, €32.41, and €36.06. CONCLUSIONS: The cost per successfully treated migraine attack was lower for patients treated with Eletriptan compared to other existing triptans in Spain.
1
Ghent University, HEDM, Meise, NA, Belgium; 2 HEDM, Meise, NA, Belgium; 3 AstraZeneca, Brussels, NA, Belgium OBJECTIVES: To assess the cost-effectiveness of nasal spray zolmitriptan 5 mg (ZOL), compared to subcutaneous sumatriptan 6 mg (SUM) in the management of moderate to severe migraine patients in Belgium.
METHODS:
A medical decision analytic model was developed in MS-Excel, reflecting patient outcomes and related management. The net response rate (headache response after 2 hours) above placebo is a primary outcome in migraine trials and was obtained from randomised clinical trials. This response rate above placebo was 52% for SUM, and 39.7% for ZOL. However, recurrence rates after initial response and within the same attack were 39% and only 25.6% respectively. Cost of non-response and cost of managing recurrence were obtained from published local literature from a health care payer perspective. Full response was defined as patients responding without recurrence. The time horizon was limited to one attack episode. RESULTS: ZOL total treatment cost was €28.02 with 43.7% full response, while SUM costed €40.95 in total with 42.19% full response (i.e. ZOL slightly dominant). Rank order stability analyses (ROSA) showed that results were very robust towards variations in cost of management (max. deviation in savings of 4%). The analysis was sensitive to treatment performance and recurrence rates, both having a weak effect on savings (max deviation in savings of 13%), but with the potential to inverse the dominant position of ZOL. CONCLUSIONS: ZOL as standard treatment in moderate to severe migraine is cost saving from the Belgian health care payer's perspective compared to SUM, with comparable effectiveness. 
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COST-EFFECTIVENESS STUDY OF RIZATRIPTAN VS. USUAL CARE IN THE TREATMENT OF MIGRAINE IN CANADA
OBJECTIVE:
In Canada, the clinical use of triptans is restricted by many health plans, despite their proven superior efficacy in the treatment of moderate to severe migraine. This analysis estimates the clinical consequences, costs and cost-effectiveness of Rizatriptan compared to other triptans and UC in Ontario, Canada. METHODS: A decision analytic model was created to estimate migraine treatment costs and clinical outcomes observed over a 24-hour period from therapy initiation, in patients with a diagnosis of moderate to severe migraine as defined by International Headache Society (IHS) criteria. Efficacy measures consisted of pain-free patients at 2 and 4 hours and those sustained pain-free for the following 2 to 24 hours. Rizatriptan was compared to other triptans based on data from a metaanalysis, and compared to UC based on other published data. Costs of therapies were used to determine incremental costs per attack aborted as well as cost per QALY. Both a Ministry of Health perspective (direct costs) and
